Description
The transformative impact of artificial intelligence (AI) on various industries is undeniable. However, for the biopharmaceutical industry, AI has yet to meet its full potential. In this webinar, 1859 will discuss its approach to rapidly generating high-quality, empirical, small molecule datasets, and its comparison to other approaches, like public data curation and traditional screening technology. Join this webinar to gain insights into how data disrupts the drug discovery paradigm and ultimately delivers new medicines to patients faster.